Novel Rx
Richard Conway RichardPAConway
1 year ago
Zou et al. Phase 2 RCT Vunakizumab, humanized IL17A in PsA. 12 week study. ACR responses shown in figure, looks similar to existing IL17As. @RheumNow #ACR24 Abstr#2581 https://t.co/Td5xlMYrAd https://t.co/Rl4gkmDFOR
Eric Dein ericdeinmd
1 year ago
A#2363
Deodhar
Bimekizumab fast time to work:
BE MOBILE 1 and 2 - rapid treatment responses with separation from PBO as early as 1-2 weeks after single dose.
@RheumNow #ACR24 https://t.co/T81Lzyoy7m
Richard Conway RichardPAConway
1 year ago
Xia et al. Upadacitinib in refractory Behcets. Open label, 8 patients. Follow-up 4-14 months. Lower disease activity 2.5 vs 1.5. Lower pred, 11.9 vs 8.1. @RheumNow #ACR24 Abstr#2515 https://t.co/ZXsJkNRlTm https://t.co/S8LhpqZ8X3
Bella Mehta bella_mehta
1 year ago
In the horizon for Knee #OA pain management - XG005 - non opioid inhibiting inflammatory and neuropathic signals via the COX enzymes and the calcium subunit. Phase 2b , placebo control, double blind study
Abst #L08 #ACR24 @RheumNow https://t.co/j4qkj1Xvbr
Eric Dein ericdeinmd
1 year ago
US biosimilar exp
Interchangeable biosimilar - can substitute for reference product wo consulting MD
Primary endpt: pharmacokinetic data
61 approved biosimilars
@RheumKay: “pts should share in financial benefits”
Currently 5-87% discount
#PBMReform @ACRheumDC
@RheumNow #ACR24 https://t.co/RqwbZalZko
Akhil Sood MD AkhilSoodMD
1 year ago
Abstract 1842: Off the shelf CAR T therapy
No lymphodepletion needed, delivering robust, targeted CD19+ B cell elimination in multiple in vitro assays
@RheumNow #ACR24
Brian Jaros, MD Dr_Brian_MD
1 year ago
If you’re starting with DMARD (according to ACR/VF guidelines) tx in TAK - MTX and AZA are probably equivalent options… MMF not so much
@RheumNow #ACR24 https://t.co/jn52ujtspo
Brian Jaros, MD Dr_Brian_MD
1 year ago
Early observational data suggesting JAK inhibitors can play a role in TAK tx
We have seen this with UPA in GCA this conference… time for SELECT-TAK !
@RheumNow #ACR24 https://t.co/B2Wa8sOFTp
Dr. John Cush RheumNow
1 year ago
#ACR24 - Featured Industry Presentations
Many of the great presentations for this meeting come from industry sponsored clinical trials and reports. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.… https://t.co/I6LMQ5xMUx https://t.co/UzTeqWUSdo
Richard Conway RichardPAConway
1 year ago
Gottenberg et al. A positive RCT in pSS! DAHLIAS study. Phase 2. 163 patients. Nipocalimab, anti-neonatal Fc receptor (FcRn) mAb. @RheumNow #ACR24 Abstr#2527 https://t.co/M7li4ZoKeY https://t.co/gV9MGnswdR
Antoni Chan MD (Prof) synovialjoints
1 year ago
Nipocalimab, an anti-neonatal Fc receptor (FcRn) mAb, reduces circulating IgG including specific autoantibodies (AAb), by selectively blocking IgG–FcRn interactions.
DAHLIAS, the first study of a FcRn blocker in SjD, showed that nipocalimab led to significant improvement vs PBO… https://t.co/zl1tEsEMAj https://t.co/qrkOD2Ccc3
Eric Dein ericdeinmd
1 year ago
A#2527 DAHLIAS, P2 Nipocalimab: Anti-FcRn Ab in Ro+ SjD IV 5 or 15 mg/kg Prim Endpt: 15 mg/kg has ClinESSDAI at w24 -6.4 v -3.7 PBO p=0.002 Improv dryness, fatigue, pain Better unstim salivary flow Best response in higher Ab titer pts Safety data good #ACRBest #ACR24 @RheumNow https://t.co/O7zahPul66
Mike Putman EBRheum
1 year ago
Phase 2 DAHLIA study in Sjogrens Anti-neonatal Fc receptor an “nipocalimab” w/remarkably encouraging results clinESSDAI significantly better at wk24, notably met QOL domains as well Finally getting good news in SjS! #ACR24 @RheumNow #ACRbest Abst#2527 https://t.co/e3uQmqJZ1o
David Liew drdavidliew
1 year ago
I have no doubt many of our RA patients will take GLP-1 agonists in the future.
Here's some data @UCLA showing significant differences in not just body weight and HbA1c, but pain.
Will be fascinating to see what it does for grumbling disease activity!
#ACR24 ABST2259 @RheumNow https://t.co/HdOPACEo3A
Poster Hall